NFE2L2 and osteogenesis imperfecta: In vitro, OI treatment also reduces fibrotic markers fibronectin, plasminogen activator inhibitor 1 (PAI-1), and α-SMA, decreases phosphorylation of p65 subunit of NF-κB; whereas stimulates antioxidant response through the increase of the nuclear factor erythroid 2-related factor (Nrf2) and reducing ROS levels in kidney epithelial cells HK-2 stimulated with TGF-β [72].